West African Minerals Corporation Board Appointment (3510K)
July 06 2017 - 8:47AM
UK Regulatory
TIDMWAFM
RNS Number : 3510K
West African Minerals Corporation
06 July 2017
For immediate release
6 July 2017
West African Minerals Corporation
("West African" or the "Company")
Board Appointment
The Board of West African Minerals Corporation is pleased to
announce that Dr Kunwar Shailubhai has been appointed as
non-executive director of the Company with immediate effect.
Dr Kunwar Shailubhai is Chief Executive Officer of AIM-traded
Tizania Life Sciences Plc and has extensive experience within the
life sciences sector, drawing on 30 years of experience in research
and development of drug candidates for treatment of
gastrointestinal disorders, inflammatory diseases and cancers. He
previously worked for a number of years at Synergy Pharmaceuticals
Inc (SGYP: NASDAQ), which he co-founded and where he served as
chief scientific officer since 2008.
Dr Kunwar Shailubhai's pioneering research programme culminated
in the development of the drug Trulance(TM) (plecanatide) which
received FDA approval in January 2017 for the treatment of adults
with chronic idiopathic constipation. A supplemental new drug
application has been submitted for FDA review of Trulance for the
treatment of adults with irritable bowel syndrome with constipation
(IBS-C). Prior to joining Tiziana Life Sciences Plc and Synergy
Pharmaceuticals Inc, Dr Kunwar Shailubhai worked at Callisto
Pharmaceuticals, Monsanto Company and as a senior staff fellow at
the National Institutes of Health (NIH).
AIM Disclosures
Further disclosures on Dr Kunwar Shailubhai as required under
Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for
Companies are as follows:
Dr Kunwar "Shailu" Shailubhai, aged 59, has held the following
directorships and / or partnerships in the previous five years:
Current Past
------------------------ -----
Tiziana Life Sciences n.a.
Plc
Rasna Therapeutics
Inc
GenSignia Life Sciences
Inc
There are no further disclosures in relation to Dr Kunwar
Shailubhai pursuant to Schedule 2(g) of the AIM Rules for
Companies.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information contact:
West African Minerals Corporation Gerard Holden +44 (0) 1624 639 396
Roland Cornish
Beaumont Cornish Limited (Nominated Adviser) Michael Cornish +44 (0)20 7628 3396
Beaufort Securities Limited (Broker) Jon Belliss +44 (0)20 7382 8300
ENDS
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADMGGNZVKGNZM
(END) Dow Jones Newswires
July 06, 2017 08:47 ET (12:47 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024